Pfizer previously said the two partners would likely produce between 2.3 billion and 2.4 billion doses this year.

BioNTech cited its new facility in the German city of Marburg and an expansion of the pair’s network of third party manufacturers and suppliers as drivers behind the larger volumes.

“Additional measures and discussions with potential partners to further expand the manufacturing capacity and network are ongoing,” it added.

As of last week, more than 200 million doses of the product, known as BNT162b2 or Comirnaty, have been supplied, while signed orders for delivery in 2021 currently amount to 1.4 billion doses, said BioNTech.

Based on this order backlog, BioNTech said it expected €9.8 billion in revenues from the product, reflecting direct sales, sales to collaboration partners, milestone payments from partners as well as a share of gross profit in the partners’ territories.

BioNTech has previously said it had a 50-50 cost and profit share agreement with Pfizer, which excludes China, and a 35% to 40% gross profit share deal with Fosun Pharma in China.

In early February, Pfizer projected Comirnaty would contribute at least US$15 billion to its 2021 group sales.